Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SCYX
#3578
SCYNEXIS, Inc.
0.7
5
+4.17%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+4.17%
Monthly Change
-6.25%
6 month change
-9.64%
Year Change
-25.00%
Previous Close
0.7
2
Open
0.7
5
Bid
Ask
Low
0.7
5
High
0.7
5
Volume
3
Markets
US Stock Market
Healthcare
SCYX
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
News
SCYNEXIS doses first patients in SCY-247 IV formulation trial
JERSEY CITY - FDA grants fast track and QIDP designations to SCYNEXIS drug
Scynexis receives 180-day extension from Nasdaq to meet listing requirements
SCYNEXIS receives $7 million annual grant for antifungal research
Guggenheim lowers SCYNEXIS stock price target to $3 after GSK trial resolution
SCYNEXIS receives $22 million from GSK as MARIO study ends
Scynexis to receive $24.3 million from GSK as MARIO study ends per new agreement
SCYNEXIS reports positive Phase 1 results for antifungal drug SCY-247
Scynexis Inc earnings beat by $0.06, revenue topped estimates
SCYNEXIS resumes Phase 3 antifungal study after FDA lift
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update